Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
Artelo Biosciences’ oral dual cannabinoid agonist showed weight loss comparable to the GLP-1 receptor agonist semaglutide in obese mice. When Artelo’s ART27.13 was used in combination with semaglutide, the active ingredient in GLP-1 drugs Ozempic and …